# reload+after+2024-01-21 13:40:55.196974
address1§Eliot Park Innovation Centre
address2§4 Barling Way
city§Nuneaton
zip§CV10 7RH
country§United Kingdom
phone§44 24 7679 6496
website§https://www.valirx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.
fullTimeEmployees§8
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D.', 'age': 45, 'title': 'CEO & Director', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 160850, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James Gerry Desler FCA', 'age': 67, 'title': 'CFO, Company Secretary & Executive Director', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 53000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kumar  Nawani', 'title': 'Head of Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Catherine Jane Tralau-Stewart Ph.D.', 'title': 'Chief Scientific Officer & Board Observer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Tarquin  Edwards', 'title': 'Head of Investor Relations & Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark  Treharne', 'title': 'Corporate Development Manager', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.605
currency§GBp
forwardEps§-1.86
exchange§LSE
quoteType§EQUITY
shortName§VALIRX PLC ORD 0.1P
longName§ValiRx plc
firstTradeDateEpochUtc§1010390400
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§000c560d-4e7e-3c40-b7cd-daaaaab66571
recommendationMean§1.0
recommendationKey§strong_buy
quickRatio§13.372
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
